Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model

Li, Huiying; Jia, Chunman; Li, Chaonan; Wang, Yan; Du, Weimin; Jiang, Hongpeng

doi:10.1007/s10120-023-01412-2

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 187 Furthermore, some compounds, such as auramycin G and Babao Dan, exert inhibitory effects on lymphangiogenesis through the downregulation of VEGFC, and curcumin hinders lymphangiogenesis by targeting the HMGB1/VEGFD axis. 188 – 190 …”

Section: Abnormal Lymphangiogenesis In Human Diseasesmentioning

confidence: 99%

Lymphatic vessel: Origin, heterogeneity, biological functions and therapeutic targets

Hu,

Zhao,

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Lymphatic vessels, comprising the secondary circulatory system in human body, play a multifaceted role in maintaining homeostasis among various tissues and organs. They are tasked with a serious of responsibilities, including the regulation of lymph absorption and transport, the orchestration of immune surveillance and responses. Lymphatic vessel development undergoes a series of sophisticated regulatory signaling pathways governing heterogeneous-origin cell populations stepwise to assemble into the highly specialized lymphatic vessel networks. Lymphangiogenesis, as defined by new lymphatic vessels sprouting from preexisting lymphatic vessels/embryonic veins, is the main developmental mechanism underlying the formation and expansion of lymphatic vessel networks in an embryo. However, abnormal lymphangiogenesis could be observed in many pathological conditions and has a close relationship with the development and progression of various diseases. Mechanistic studies have revealed a set of lymphangiogenic factors and cascades that may serve as the potential targets for regulating abnormal lymphangiogenesis, to further modulate the progression of diseases. Actually, an increasing number of clinical trials have demonstrated the promising interventions and showed the feasibility of currently available treatments for future clinical translation. Targeting lymphangiogenic promoters or inhibitors not only directly regulates abnormal lymphangiogenesis, but improves the efficacy of diverse treatments. In conclusion, we present a comprehensive overview of lymphatic vessel development and physiological functions, and describe the critical involvement of abnormal lymphangiogenesis in multiple diseases. Moreover, we summarize the targeting therapeutic values of abnormal lymphangiogenesis, providing novel perspectives for treatment strategy of multiple human diseases.

show abstract

Section: Abnormal Lymphangiogenesis In Human Diseasesmentioning

confidence: 99%